Banyu Receives Japan Manufacturing Approval for Fosamax, Treatment Drug for Osteoporosis.Tokyo, Japan, Aug 3, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Banyu Pharmaceutical Co., Ltd. obtained manufacturing approval for Fosamax Plus D - generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. : aledronate sodium - on July 26. Fosamax was first launched in Japan in 2001 and since has proven to be an effective drug for patients of post menopausal osteoporosis, indicating an efficiency reduction of cells that cause bone loss. Fosamax is prescribed to 7 million patients worldwide. Taken once a daily, it can reduce the risk of vertebral compression fracture vertebral compression fracture Compression fracture of back Orthopedics A traumatic fracture of a vertebral body which may occur in a background of osteoporosis or malignancy and cause kyphosis and spinal cord pressure. See Herniated disk. by 90% and femoral femoral /fem·o·ral/ (fem´or-al) pertaining to the femur or to the thigh. fem·o·ral adj. Of or relating to the femur or thigh. fracture by 51%. It also showed increased drug compliance by having it prescribed once a week. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion